Does Rallies show 13F holders for COGT?

Yes. Rallies tracks hedge fund and 13F ownership data for COGT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is COGT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for COGT. It does not provide personalized investment advice.

COGT (Cogent Biosciences, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Cogent Biosciences, Inc. Common Stock (COGT) is a publicly traded Healthcare sector company. As of May 21, 2026, COGT trades at $33.05 with a market cap of $5.36B and a P/E ratio of -15.19. COGT moved +5.44% today. Year to date, COGT is -3.90%; over the trailing twelve months it is +520.06%. Its 52-week range spans $3.72 to $43.73. Analyst consensus is strong buy with an average price target of $52.10. Rallies surfaces COGT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns COGT stock?

Hedge funds tracked by Rallies that own COGT include Duquesne Family, Redmile Group, Orbimed Advisors, Panagora Asset, and Farallon Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cogent Biosciences, Inc. Common Stock.

COGT Key Metrics

Key financial metrics for COGT
Metric	Value
Price	$33.05
Market Cap	$5.36B
P/E Ratio	-15.19
EPS	$-2.16
Dividend Yield	0.00%
52-Week High	$43.73
52-Week Low	$3.72
Volume	1.54M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-328.94M
Gross Margin	0.00%

Top Hedge Funds Holding COGT

Duquesne Family holds 2.21M shares of COGT, changed +109.00% as of Dec 31, 2025.
Redmile Group holds 688.04K shares of COGT, changed -52.15% as of Mar 31, 2026.
Orbimed Advisors holds 322.10K shares of COGT, changed -13.18% as of Mar 31, 2026.
Panagora Asset holds 44.04K shares of COGT, changed +199.36% as of Sep 30, 2025.
Farallon Capital holds 17.00K shares of COGT, changed +0.00% as of Mar 31, 2026.

Latest COGT News

Cogent Biosciences slips as investors digest Q1 loss and long PDUFA timeline — May 6, 2026
Cogent Biosciences Secures $866M Cash Runway into 2028, Eyes Dual Bezuclastinib Launches — May 5, 2026
Cogent Biosciences rises as bezuclastinib FDA filings near and ASCO catalyst approaches — May 1, 2026
Cogent Biosciences slips as 7M-share Form 144 overhang pressures biotech rally — Apr 29, 2026
Cogent Biosciences dips as Form 144 flags potential 7 million-share resale overhang — Apr 10, 2026

Recent COGT Insider Trades

Fairmount Funds Management LLC sold 7.00M (~$242.62M) on Mar 31, 2026.
Fairmount Funds Management LLC sold 3.50M (~$127.40M) on Jan 22, 2026.
Kearns Evan sold 65.00K (~$2.52M) on Dec 26, 2025.

COGT Analyst Consensus

11 analysts cover COGT: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $52.10.

Common questions about COGT

Who owns COGT stock?: Hedge funds tracked by Rallies that own COGT include Duquesne Family, Redmile Group, Orbimed Advisors, Panagora Asset, and Farallon Capital. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cogent Biosciences, Inc. Common Stock.
Does Rallies show 13F holders for COGT?: Yes. Rallies tracks hedge fund and 13F ownership data for COGT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is COGT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for COGT. It does not provide personalized investment advice.